Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: Subcutaneous vs Intravenous Dostarlimab in Endometrial Cancer
NCT07860450Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Nov 2026
- Primary completion
- Nov 2030
01
Overview
A Phase 3 trial of dostarlimab in endometrial cancer (EC), sponsored by GSK. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07860450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07860450.